-
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
29 Mar 2024 03:47 GMT
… Dose First Patient in Second Quarter of 2024
Received Safety … first patient in the second quarter of this year … of 2024.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a … intake while increasing energy expenditure, thus potentially resulting in …
-
Walgreens Boots Alliance Reports Fiscal 2024 Second Quarter Results
28 Mar 2024 11:21 GMT
…
Overview of Second Quarter Results
WBA second quarter sales increased 6 … .S. Retail Pharmacy segment had second quarter sales of $ … sales
Fiscal 2024 second-quarter comparable sales and … and equipment (capital expenditures), plus acquisition related payments …
-
Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript
27 Mar 2024 16:02 GMT
… morning and welcome to Syros Pharmaceuticals Fourth Quarter and Full … expenses and capital expenditure requirements into the second quarter of 2025, beyond … for the cash runway into Q2 of 2025, it seems … us to get into the second quarter of 2025. Phil Nadeau …
-
Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript
29 Mar 2024 02:29 GMT
… understood about certain active pharmaceutical ingredients and marketed products … our R&D expenditure is predicated on ongoing … 3 design in the second quarter of 2024. We’ve … going through specialty pharmaceutical -- specialty pharmacies, IQVIA isn’t …
-
P3 Health Partners Inc. (PIII) Q4 2023 Earnings Call Transcript
29 Mar 2024 02:28 GMT
… although potentially some in the second quarter. I want to finish by … entire network of specialists and pharmaceutical costs that allow us … , the Part B cost, expenditures, et cetera. And as … me say, the Part B expenditures have been significantly higher, …
-
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
28 Mar 2024 11:05 GMT
Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company’s promising research platform …
-
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
28 Mar 2024 11:00 GMT
MALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today …
-
Biopharma Layoffs Roundup
27 Mar 2024 17:18 GMT
… 2023.
In its second quarter news release, Biogen … worldwide under two divisions: Pharmaceuticals and Diagnostics.
Novavax … reducing its annual expenditure by around 40% … multiple sclerosis.
Ferring Pharmaceuticals
Headquarters: Saint-Prex, …
-
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
27 Mar 2024 12:00 GMT
–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin–
–Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is enrolling and ENLIGHTEN-Cirrhosis in MASH patients with compensated …
-
EDAP Reports Fourth Quarter and Full-Year 2023 Financial Results
27 Mar 2024 11:00 GMT
Record Q4 2023 total revenue of EUR 19.6 million ($21.3 million USD) increased 24.8% over Q4 2022
Record Q4 2023 HIFU revenue of EUR 7.5 million ($8.1 million USD), an increase of 38.8% over Q4 2022
Record full-year 2023 total revenue of EUR 60.4 million ( …